Top

Published in:

01-02-2017 | Focussed Research Review

Immunotherapy after hematopoietic stem cell transplantation using umbilical cord blood-derived products

Authors: Aurore Saudemont, J. Alejandro Madrigal

Published in: Cancer Immunology, Immunotherapy | Issue 2/2017

Abstract

Umbilical cord blood (UCB) is being increasingly used as a source of hematopoietic stem cells (HSC) for transplantation. UCB transplantation (UCBT) has some advantages such as less stringent HLA-matching requirements, fast availability of the graft and reduced incidence and severity of graft-versus-host disease. However, UCBT is also associated with a higher incidence of infection, graft failure, slow engraftment and slow immune reconstitution. UCB is mainly used as a source of HSC; however, it is also rich in immune cells that could be used to treat some of the main complications post-UCBT as well as other diseases, thus implicating the use of UCB for immunotherapy. Here, we aim to describe some of the therapies currently developed that use UCB as a cell source, focusing in particular on regulatory T cells and natural killer cells.

Wing K, Karlsson H, Rudin A, Suri-Payer E (2002) Characterization of human CD25⁺ CD4⁺ T cells in thymus, cord and adult blood. Immunology 106:190–199CrossRefPubMedPubMedCentral

Thornton AM, Shevach E (2000) Suppressor effector function of CD4⁺ CD25⁺ immunoregulatory T cells is antigen nonspecific. J Immunol 164:183–190CrossRefPubMed

Trzonkowski P, Myśliwska J, Dobyszuk A, Myśliwski A (2004) CD4⁺ CD25⁺ T regulatory cells inhibit cytotoxic activity of T CD8⁺ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 112:258–267CrossRefPubMed

Ghiringhelli F, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L (2005) CD4⁺ CD25⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075–1085CrossRefPubMedPubMedCentral

Nakamura K, Fuss I, Pedersen A, Harada N, Nawata H, Strober W (2004) TGF-beta 1 plays an important role in the mechanism of CD4⁺ CD25⁺ regulatory T cell activity in both humans and mice. J Immunol 172:834–842CrossRefPubMed

Annacker O, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A (2001) CD25⁺ CD4⁺ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166:3008–3018CrossRefPubMed

Collison LW, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11:1093–1101CrossRefPubMedPubMedCentral

Pandiyan P, Ishihara S, Reed J, Lenardo MJ (2007) CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells. Nat Immunol 8:1353–1362CrossRefPubMed

Schmidt A, Oberle N, Krammer PH (2012) Molecular mechanisms of Treg-mediated T cell suppression. Front Immunol 3:51. doi:10.3389/fimmu.2012.00051.eCollection PubMedPubMedCentral

10.

Trzonkowski P, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A (2009) First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4⁺ CD25⁺ CD127-T regulatory cells. Clin Immunol 133:22–26CrossRefPubMed

11.

Di Ianni M, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF (2011) Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117:3921–3928CrossRefPubMed

12.

Martelli MF, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi A (2014) HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124:638–644CrossRefPubMed

13.

Edinger M, Hermann P (2011) Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 23:679–684CrossRefPubMed

14.

Theil A, Oelschlägel U, Maiwald A, Döhler D, Oßmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, Trautmann-Grill K, von Bonin M, Platzbecker U, Ehninger G, Bonifacio E, Bornhäuser M (2015) Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy 17:473–486CrossRefPubMed

15.

Figueroa-Tentori D, Querol S, Dodi IA, Madrigal A, Duggleby R (2008) High purity and yield of natural tregs from cord blood using a single step selection method. J Immunol Methods 339:228–235CrossRefPubMed

16.

Hoffmann P, Boeld TJ, Doser K, Piseshka B, Andreesen R, Edinger M (2006) Only the CD45RA⁺ subpopulation of CD4⁺ CD25 high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108:4260–4267CrossRefPubMed

17.

Miyara M, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S (2009) Functional delineation and differentiation dynamics of human CD4⁺ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911CrossRefPubMed

18.

Wing K, Sandström K, Lundin SB, Suri-Payer E, Rudin A (2005) CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells from human thymus and cord blood suppress antigen-specific T cell responses. Immunology 115:516–525CrossRefPubMedPubMedCentral

19.

Milward K, Hester J, Figueroa-Tentori D, Madrigal A, Wood KJ (2013) Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation 95:85–93CrossRefPubMedPubMedCentral

20.

Wing K, Kollberg G, Lundgren A, Harris RA, Rudin A, Lundin S, Suri-Payer E (2003) CD4 T cell activation by myelin oligodendrocyte glycoprotein is suppressed by adult but not cord blood CD25⁺ T cells. Eur J Immunol 33:579–587CrossRefPubMed

21.

Fujimaki W, Takahashi N, Ohnuma K, Nagatsu M, Kurosawa H, Yoshida S, Dang NH, Uchiyama T, Morimoto C (2008) Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Clin Dev Immunol 2008:305859. doi:10.1155/2008/305859 CrossRefPubMedPubMedCentral

22.

Brunstein CG, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE (2011) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117:1061–1070CrossRefPubMedPubMedCentral

23.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE (2016) Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile and clinical effect. Blood 127(8):1044–1051. doi:10.1182/blood-2015-06-653667 CrossRefPubMed

24.

Parmar S, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ (2014) Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16:90–100CrossRefPubMed

25.

Brunstein CG, Blazar BR, Miller JS, Cao Q, Hippen KL, McKenna DH, Curtsinger J, McGlave PB, Wagner JE (2013) Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. Biol Blood Marrow Transpl 19(8):1271–1273. doi:10.1016/j.bbmt.2013.06.004 CrossRef

26.

Kotylo PK, Yoder MC, Engle WA, Bolinger CD (1990) Rapid analysis of lymphocyte subsets in cord blood. Am J Clin Pathol 93:263–266CrossRefPubMed

27.

Luevano M, Alnabhan R, Querol S, Khakoo S, Madrigal A, Saudemont A (2012) The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol 73:248–257CrossRefPubMed

28.

Cooper MA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640CrossRefPubMed

29.

Gaddy J, Broxmeyer HE (1995) Cord blood natural killer cells are functionally and phenotypically immature but readily respond to interleukin-2 and interleukin-12. J Interf Cytokine Res 15:527–536CrossRef

30.

Wang Y, Zheng X, Wei H, Sun R, Tian Z (2007) High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol 4:377–382PubMed

31.

Dalle JH, Wagner E, Blagdon M, Champagne J, Champagne MA, Duval M (2005) Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res 57:649–655CrossRefPubMed

32.

Alnabhan R, Madrigal A, Saudemont A (2014) Differential activation of cord blood and peripheral blood natural killer cells by cytokines. Cytotherapy 17:73–85CrossRefPubMed

33.

Burns LJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS (2003) IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transpl 32:177–186CrossRef

34.

Ruggeri L, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100CrossRefPubMed

35.

Locatelli F, Brescia L, Merli P (2014) Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol 26:173–179CrossRefPubMed

36.

Domogala A, Madrigal JA, Saudemont A (2015) Natural killer cell immunotherapy: from bench to bedside. Front Immunol 6:264. doi:10.3389/fimmu.2015.00264.eCollection CrossRefPubMedPubMedCentral

37.

Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ (2013) Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8:e76781. doi:10.1371/journal.pone.0076781.eCollection CrossRefPubMedPubMedCentral

38.

Escobedo-Cousin M, Jackson N, Laza-Briviesca R, Ariza-McNaughton L, Luevano M, Derniame S, Querol S, Blundell M, Thrasher A, Soria B, Cooper N, Bonnet D, Madrigal A, Saudemont A (2015) Natural killer cells improve hematopoietic stem cell engraftment by increasing stem cell clonogenicity in vitro and in a humanized mouse model. PLoS One 10(10):e0138623. doi:10.1371/journal.pone.0138623.eCollection CrossRefPubMedPubMedCentral

39.

Yoon SR, Yang SH, Ahn KH, Lee JH, Lee JH, Kim DY, Kang YA, Jeon M, Seol M, Ryu SG, Chung JW, Choi I, Lee KH (2010) Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transpl 45:1038–1046CrossRef

40.

Spanholtz J, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H (2010) High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 5:e9221. doi:10.1371/journal.pone.0009221 CrossRefPubMedPubMedCentral

41.

Grzywacz B, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR (2006) Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108:3824–3833CrossRefPubMedPubMedCentral

42.

Luevano M, Domogala A, Blundell M, Jackson N, Pedroza-Pacheco I, Derniame S, Escobedo-Cousin M, Querol S, Thrasher A, Madrigal A, Saudemont A (2014) Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells. PLoS One 9:e87086. doi:10.1371/journal.pone.0087086.eCollection CrossRefPubMedPubMedCentral

43.

Passweg JR, Meyer-Monard S, Heim D, Stern M, Kühne T, Favre G, Gratwohl A (2004) Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18:1835–1838CrossRefPubMed

44.

Koehl U, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33:261–266CrossRefPubMed

45.

Miller JS, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057CrossRefPubMed

46.

Rubnitz JE, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:955–959CrossRefPubMedPubMedCentral

47.

Bachanova V, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59:1739–1744CrossRefPubMedPubMedCentral

48.

Curti A, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118:3273–3279CrossRefPubMed

49.

Stern M, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, Tichelli A, Schwabe D, Koehl U (2013) Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transpl 48:433–438CrossRef

50.

Bachanova V, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855–3863CrossRefPubMedPubMedCentral

Title: Immunotherapy after hematopoietic stem cell transplantation using umbilical cord blood-derived products
Authors: Aurore Saudemont
J. Alejandro Madrigal
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 2/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1852-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Cytokine-induced killer cells hunt individual cancer cells in droves in a mouse model

The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress

Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies

Designing therapeutic cancer vaccines by mimicking viral infections

Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon

Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models

Keynote webinar | Spotlight on antibody–drug conjugates in cancer